• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

以色列盲症发病率和病因的时间趋势。

Time trends in the incidence and causes of blindness in Israel.

机构信息

Goldschleger Eye Institute, Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel.

出版信息

Am J Ophthalmol. 2012 Feb;153(2):214-221.e1. doi: 10.1016/j.ajo.2011.08.035.

DOI:10.1016/j.ajo.2011.08.035
PMID:22264945
Abstract

PURPOSE

To evaluate time trends in the incidence and causes of new cases of blindness in Israel between 1999 and 2008.

DESIGN

Descriptive, retrospective population-based study.

METHODS

During the decade of the study, 19 862 inhabitants of Israel were newly registered as legally blind. Data were retrieved from the 1999 to 2008 annual reports of the National Registry of the Blind in Israel and were reviewed retrospectively. Specific rates by age, gender, calendar year, and cause of blindness were calculated. Total and cause-specific annual age-standardized rates were calculated as well. Findings were evaluated by the use of Poisson regression models.

RESULTS

The age-standardized rate of incidence of newly registered legal blindness at the end of the studied decade was half of that at the beginning, declining from 33.8 per 100 000 in 1999 to 16.6 per 100 000 in 2008. The decline mainly was attributable to a decreased incidence of blindness resulting from age-related macular degeneration, glaucoma, diabetic retinopathy, and cataract.

CONCLUSIONS

Contemporary interventions in ophthalmology combined with widely available universal free access to healthcare seem to be effective in causing a major reduction in the incidence of blindness.

摘要

目的

评估 1999 年至 2008 年期间以色列新发生盲病例的发病率和病因的时间趋势。

设计

描述性、回顾性基于人群的研究。

方法

在研究的十年期间,有 19862 名以色列居民被新登记为法定盲人。数据取自以色列全国盲人登记处 1999 年至 2008 年的年度报告,并进行了回顾性审查。按年龄、性别、日历年度和致盲原因计算了特定的发病率。还计算了总发病率和病因特异性的年龄标准化发病率。使用泊松回归模型评估了发现。

结果

在研究结束时,新登记的法定失明发病率的年龄标准化率为研究开始时的一半,从 1999 年的每 100000 人 33.8 例降至 2008 年的每 100000 人 16.6 例。这种下降主要归因于与年龄相关的黄斑变性、青光眼、糖尿病视网膜病变和白内障引起的失明发病率下降。

结论

眼科的现代干预措施与广泛普及的全民免费医疗相结合,似乎有效地降低了失明的发病率。

相似文献

1
Time trends in the incidence and causes of blindness in Israel.以色列盲症发病率和病因的时间趋势。
Am J Ophthalmol. 2012 Feb;153(2):214-221.e1. doi: 10.1016/j.ajo.2011.08.035.
2
Estimation of prevalence and incidence rates and causes of blindness in Israel, 1998-2003.1998 - 2003年以色列失明患病率、发病率及病因估计
Isr Med Assoc J. 2006 Dec;8(12):880-1.
3
[Causes of blindness in the year 2000 in Israel].[2000年以色列失明的原因]
Harefuah. 2003 Feb;142(2):94-6, 160.
4
The role of diabetic retinopathy in blindness and poor sight in Split-Dalmatia County 2000-2010.2000 - 2010年糖尿病视网膜病变在斯普利特 - 达尔马提亚县失明和视力低下中的作用。
Acta Clin Croat. 2013 Dec;52(4):448-52.
5
Registered blindness and low vision in Kuwait.科威特的登记失明和视力低下情况。
Ophthalmic Epidemiol. 2005 Aug;12(4):251-7. doi: 10.1080/09286580591005813.
6
[Causes of blindness in Israel].[以色列失明的原因]
Harefuah. 2000 Feb 15;138(4):276-8, 342.
7
Time trends in the incidence and causes of blindness in Israel.以色列失明发病率及病因的时间趋势。
Am J Ophthalmol. 2013 Feb;155(2):404. doi: 10.1016/j.ajo.2012.09.017.
8
Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010.丹麦与年龄相关的黄斑变性导致法定盲的发病率:2000 年至 2010 年。
Am J Ophthalmol. 2012 Feb;153(2):209-213.e2. doi: 10.1016/j.ajo.2011.10.016.
9
Trends in the incidence and causes of severe visual impairment and blindness in children from Israel.以色列儿童严重视力损害和失明的发病率及病因趋势。
J AAPOS. 2015 Jun;19(3):260-5.e1. doi: 10.1016/j.jaapos.2015.04.002.
10
National Registry for the Blind in Israel: estimation of prevalence and incidence rates and causes of blindness.以色列全国盲人登记处:失明患病率、发病率及病因估计
Ophthalmic Epidemiol. 2003 Oct;10(4):267-77. doi: 10.1076/opep.10.4.267.15910.

引用本文的文献

1
Tailored Anti-VEGF Therapy with New Generation Optimizations (TANGO) Treatment Regimen for Neovascular Age-Related Macular Degeneration: Rationale, Design, and Simulation Study.用于新生血管性年龄相关性黄斑变性的新一代优化定制抗血管内皮生长因子(VEGF)治疗(TANGO)方案:原理、设计与模拟研究
Clin Ophthalmol. 2025 Apr 29;19:1435-1441. doi: 10.2147/OPTH.S518756. eCollection 2025.
2
The Spectrum of Functional, Structural, and Patient-Reported Outcomes in Intermediate Age-Related Macular Degeneration: A MACUSTAR Study Report.中年相关性黄斑变性的功能、结构及患者报告结局谱:一项MACUSTAR研究报告
Ophthalmologica. 2025;248(2):101-111. doi: 10.1159/000543231. Epub 2025 Feb 3.
3
Global certification of visual impairment registries: A scoping review.
视力损害登记的全球认证:一项范围综述。
Acta Ophthalmol. 2025 Feb;103(1):7-15. doi: 10.1111/aos.16763. Epub 2024 Sep 28.
4
The Reinforced Treat-and-Extend Protocol for Exudative Age-Related Macular Degeneration: Retrospective Assessment of 24-Month Real-World Outcomes in France.渗出性年龄相关性黄斑变性的强化治疗与延长方案:法国24个月真实世界结局的回顾性评估
Ophthalmol Ther. 2024 Jun;13(6):1647-1667. doi: 10.1007/s40123-024-00938-7. Epub 2024 Apr 16.
5
Sight impairment registration in Trinidad: trend in causes and population coverage in comparison to the National Eye Survey of Trinidad and Tobago.特立尼达和多巴哥视力障碍登记:与特立尼达和多巴哥国家眼调查相比,病因和人口覆盖范围的趋势。
Eye (Lond). 2024 Aug;38(11):2134-2142. doi: 10.1038/s41433-024-02943-3. Epub 2024 Feb 7.
6
Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration.新生血管性年龄相关性黄斑变性对健眼进行真实世界监测的后果
Life (Basel). 2023 Jan 31;13(2):385. doi: 10.3390/life13020385.
7
Visual impairment due to age-related macular degeneration during 40 years in Finland and the impact of novel therapies.在芬兰,40 年间与年龄相关的黄斑变性导致的视力障碍,以及新型疗法的影响。
Acta Ophthalmol. 2023 Feb;101(1):57-64. doi: 10.1111/aos.15224. Epub 2022 Aug 1.
8
Ranibizumab port delivery system in neovascular age-related macular degeneration.雷珠单抗玻璃体内注射植入系统治疗新生血管性年龄相关性黄斑变性
Ther Adv Ophthalmol. 2022 Feb 7;14:25158414211072623. doi: 10.1177/25158414211072623. eCollection 2022 Jan-Dec.
9
Anti-VEGF therapies for age-related macular degeneration: a powerful tactical gear or a blunt weapon? The choice is ours.抗血管内皮生长因子治疗年龄相关性黄斑变性:强有力的战术装备还是钝器?选择权在我们手中。
Graefes Arch Clin Exp Ophthalmol. 2021 Dec;259(12):3561-3567. doi: 10.1007/s00417-021-05451-2. Epub 2021 Oct 20.
10
A novel EyePhone© App for improving adherence to glaucoma therapy.一款用于提高青光眼治疗依从性的新型 EyePhone© App。
Graefes Arch Clin Exp Ophthalmol. 2021 May;259(5):1253-1262. doi: 10.1007/s00417-021-05091-6. Epub 2021 Feb 2.